#AAO22 conference in Chicago (Photo credit: Associate editor Kyle LaHucik)
September 30, 2022 05:30 PM EDTUpdated October 1, 11:22 AM
R&D
Pharma

#AAO22: In bid for first FDA nod in ge­o­graph­ic at­ro­phy, Apel­lis claims an­oth­er first in eye dis­ease field

Kyle LaHucik

Senior Reporter

CHICA­GO — Eight weeks be­fore pa­tients and in­dus­try find out if the FDA ap­proves the first treat­ment for ge­o­graph­ic at­ro­phy, an ad­vanced form of age …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times